Core Insights - Trinity Biotech has received a significant order for 9 million units of its TrinScreen HIV screening product, indicating a recovery in the global HIV testing market [1][2][4] - The company achieved positive Adjusted EBITDA in Q3 2025 and anticipates further profitability growth in Q1 and Q2 2026 through its Comprehensive Transformation Plan [1][8][10] TrinScreen HIV Order - The order reflects renewed commitment from global health organizations to support HIV screening, particularly in heavily affected regions [2] - TrinScreen HIV is a WHO-prequalified rapid diagnostic test designed for high-volume screening, providing reliable results in various clinical settings [2] Manufacturing and Supply Chain - Trinity Biotech will produce the tests through a WHO-approved outsourced manufacturing process, allowing for efficient scalability [3] - The company expects to fulfill the order in Q4 2025 and Q1 2026, adjusting its manufacturing and supply chain to meet increased demand [3] Financial Performance - Revenues for Q3 2025 increased by 32% to $14.3 million compared to $10.8 million in Q2 2025, driven by a $2.1 million increase in rapid HIV test sales and a rise in haemoglobin product sales [8] - Gross profit for Q3 2025 was $6.5 million, with an increase in gross margin from 42.6% to 45.2% due to operational changes [8] - Adjusted EBITDA for Q3 2025 was $0.5 million, a significant improvement from negative $2.1 million in Q2 2025 [8] Strategic Positioning - The order is expected to positively impact revenue and profitability, highlighting the company's strategic position in the global infectious disease diagnostics market [4] - The company is focused on immediate growth opportunities and expanding into international markets with new product offerings [7][14] Management Transition - Susan O'Connor has completed her term as interim Chief Financial Officer, with Paul Murphy promoted to the role [10]